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Sharing genomic research data through
controlled-access databases has increased
in recent years. Policymakers and funding
organizations endorse genomic data shar-
ing in order to optimize the use of public
funds and to increase the statistical power
of databases. Well-established data access
arrangements and data access committees
(DACs)—responsible for reviewing and
managing requests for access to genomic
databases—are therefore central for
implementing the policies and principles
of data sharing. This article aims to inves-
tigate the functionality of DACs through
the perspective of existing practices.
D ata access committees (DACs) are anintegral component of managingaccess to genomic databases. DACs
are responsible for reviewing, approving or
disapproving requests from potential users
for a variety of controlled-access genomic
databases (Fortin et al, 2010; Kaye &
Hawkins, 2014). Owing to the complexity of
studies and various ethical and legal issues,
DACs usually are independent commissions,
rather than individual researchers who
decide who gets access: “the tradition in
which custodian principal investigators
themselves made access decisions has gener-
ally been giving way to more consultative
decision-making with independent input”
(Lowrance, 2006). In fact, an independent
DAC is better placed to ensure fair and
informed decision-making about data
access. This includes addressing concerns
regarding the potential force identifiability of
genomic data, adequacy of the original
consent for collected data, the quality of the
data and protecting data producers’ publica-
tion rights while enabling a timely and
broad access to databases for many users
(Kaye et al, 2009; O’Brien, 2009; McGuire
et al, 2011).
DACs, however, function in different
ways. While some large research or funding
organizations such as the US National Insti-
tute of Health (NIH) constructed their own
databases and use central DACs to manage
access requests, other DACs are located
within study groups or consortia. An over-
view of the current practices of DACs reveals
that some aspects need to be improved in




Access to data sets in some public databas-
es, such as the European Genome-phenome
Archive (EGA), is managed through local
DACs in a decentralized fashion. For users,
this means that they have to adhere to a
variety of access arrangements adopted by
each DAC. In the absence of established
guidelines and criteria, one can expect a
considerable plurality in the practices of
DACs. A preliminary review of 212 DACs
listed in the EGA reveals that only a few of
these committees are sufficiently described
on the corresponding EGA web page. In the
majority of cases, it provides only the infor-
mation for a DAC’s contact person, which
makes it difficult if not impossible to
investigate the membership of the DAC, or
its guidelines and the procedures it uses to
evaluate access requests. This begs the ques-
tion whether such scarcity of information is
an indication of underdeveloped access
arrangements or a lack of proper communi-
cation of existing arrangements. In any
sense, this lack of transparency may fail to
adequately inform data users how DACs
assess requests, thus adversely affecting
data sharing practices. In comparison with
single or small studies, DACs for institutions
and genomic consortia make general infor-
mation more readily available on their web
pages or through the relevant publications.
Lack of funding and motivation is proba-
bly the reason for the limited investment in
developing and communicating adequate
access arrangements for small studies.
Funding agencies could therefore take the
lead in designing adequate data access
arrangements or developing central DACs
with adequate financial support to comply
with those arrangements. The database of
genotypes and phenotypes (dbGaP),
designed to store results of NIH-sponsored
human genomic studies, exemplifies this
centralized approach. Within this database,
16 DACs “review requests for consistency
with any data use limitations and approve,
disapprove or return requests for revision”,
except for large studies in which a local
DAC leads the review (Paltoo et al, 2014).
Small studies could thus benefit from a
central DAC infrastructure that follows the
central access arrangements policies, such
as the recent NIH policy for genomic data
sharing (http://gds.nih.gov/PDF/NIH_GDS_
Policy.pdf). Collaboration of small DACs to
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“develop regional or national policy consor-
tia” would be an alternative solution (Lemke
et al, 2011). Nevertheless, the interests
and concerns of researchers differ from one
study to another and must be considered
when adopting a centralized approach to
data access. Moreover, a complex or
cumbersome access arrangement that is not
designed properly could also impede the effi-
ciency of a centralized model.
Harmonization of data sharing practices
has emerged as a priority in data-intensive
research on an international level. Biobank-
ing and Biomolecular Resources Research
Infrastructures and the international Public
Population Project in Genomics and Society
(P3G) are international initiatives that offer
tools to facilitate governance of genomic
data sharing and global access to databases.
P3G has prepared a model of generic access
agreements to address issues relevant to
delivery, privacy, security, liability, intellec-
tual property, publication, reporting and
termination of the agreement (Knoppers
et al, 2013). In the same line, the Global
Alliance for Genomics and Health has
adopted a Framework for Responsible Sharing
of Genomic and Health-Related Data to
support an international agenda for data
sharing (Knoppers, 2014). Although the
harmonization of data access agreements
would facilitate data access at a global level,
it should consider local legislation with
respect to processing personal data and the
responsibilities of data custodians, which
may vary across jurisdictions.
Finally, procedures to evaluate qualified
researchers and acceptable research studies
are not often well-defined in data access
arrangements. Data users may be asked to
provide contact information, a list of recent
publications and a description of the
proposed research. Delineation of such crite-
ria by DACs is important to ensure the fair-
ness of access assessment procedures.
Concurrently, the independence of the DACs
should promote neutral evaluation of data
requests separate from personal consider-
ations between data producers and users,
especially considering potential conflict of
interests. This highlights a need for an entity
to which complaints about DAC decisions
can be referred to.
Beyond the data producers and the users’
interests and concerns, the pertinent data
access arrangements should also be attentive
to the interests and concerns of data subjects.
To this end, it is pivotal to obtain more
insights about the concerns of data subjects
on an individual or a group level in order to
inform the future data access decisions by
DACs. The significance of such inquiries is
accentuated given the shortcomings of tradi-
tional mechanisms such as one-time broad
consent where group-based considerations
are rarely addressed.
Lack of sufficient oversight mechanisms
In principle, duties and responsibilities of
data users are articulated through contrac-
tual agreements, where failure to comply
sets legitimate grounds to revoke access
permissions (Joly et al, 2011). These agree-
ments encompass various aspects of data
use, ranging from security of data storage to
the publication of results, in order to respect
the rights of research participants and data
producers. Moreover, DACs can require
compliance with certain standards to assure
that effective security protection measures
are in place including physical protections,
administrative discipline and cyber security
(Lowrance, 2012).
Currently, oversight mechanisms over
enforcement of agreements and standards
are not thoroughly elaborated. Some data
access policies already consider issues such
as auditing data use by DACs and handling
reports from users. Yet, such sporadic
approaches fail to meet needs for consistent
and ongoing oversight. Owing to the distance
between data producers and data users—and
the potential lack of expertise within DACs
to deal with technical features of data secu-
rity systems in various institutions—the
feasibility of an effective and robust mecha-
nism for data access oversight is question-
able (Kaye et al, 2009). Various regulatory
measures in different countries regarding
personal data protection and secondary use
of research data also make it harder to
perform efficient oversight on data use
across countries.
To date, a few cases of violation of the
contractual agreements have been reported,
which mainly resulted from disrespecting
publication policies such as publication
embargoes (Holden, 2009). Subsequently,
this highlights the role of journal editors or
reviewers to identify infringements in using
genomic research data (Nanda & Kowalczuk,
2014). The complexity of data use arrange-
ments makes it a shared responsibility of all
relevant parties to ensure that publication
requirements are communicated clearly and
followed up. In addition, it would be helpful
to analyse whether data sharing practices
have so far generated any other material or
moral harm to the involved parties. Not least
for the sake of such investigation, identifying
violators of access arrangements and notify-
ing stakeholders of breaches should be
streamlined. The results of such investiga-
tion will assist to fine-tune the current over-
sight mechanisms and sanctions if needed.
In the absence of such ongoing overview, it
is possible that the current protective mecha-
nisms are not adequate to deal with the
magnitude and scope of the associated risks.
Lack of clarity in relationships
between DACs and ethics committees
The relationship between DACs and institu-
tional review boards/research ethics
committees (IRBs/RECs) should be better
defined and more transparent. DACs often
refrain from adding another layer of ethics
review, seeing it as the responsibility of data
users to satisfy the requirements for ethics
approval. In some instances, DACs require
an official ethics approval document from
the home institution. On some occasions,
DACs have undertaken further evaluation of
the proposed research uses, particularly
when there are ethical concerns. It is not
clear, however, whether these DACs intend
to systematically develop an ethical review
or refer specific cases to the ethics commit-
tees at researchers’ home institutions, or
request further evaluation by the data user’s
institution. In any event, DAC’s review
should dovetail with that of IRBs/RECs to
avoid redundancies. Again, guiding princi-
ples and standards in order to streamline the
practices and involvement of ethics commit-
tees at an international level could help to
better define this relationship.
Finally, growing data-intensive research
illustrates the need for and value of globally
accessible data. This will transform current
approaches to review and the responsibilities
of IRBs/RECs and DACs. An optimal review
should be responsive and proportionate to
the particularities of research with genomic
data, which differ from the physical risks
associated with, say, clinical trial studies.
Designing access reviews regardless of the
type of data and the risks and benefits associ-
ated with the research proposal contradicts
the principle of proportionality. It is there-
fore crucial to develop clear criteria of risks
associated with genomic research. This
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tailored approach to review depends on the
sensitivity of the data used and mechanisms
to safeguard privacy and confidentiality.
Developing thorough and efficient data
access arrangements is a key to promoting
research that uses genomic data. DACs have
a critical role in implementing arrangements
that are framed in accord with the overarch-
ing principles of genomic data sharing.
In order to approve access requests to
controlled-access databases, DACs should
aim for consistency. Transparent guidelines
and criteria for qualified researchers and
research purposes should be set and
communicated adequately. Guidelines and
policy statements are well placed to promote
best practices, particularly where local regu-
lations do not address the associated issues
or there is a need for clarifications. In
essence, general guidelines are valued as
complementary documents prepared for
advisory purposes. Benefiting from profes-
sional and expert groups expertise, guidelines
could provide practical recommendations in
leading data submission, storage and distri-
bution. Involving various stakeholders and
seeking a broader consensus will ensure the
comprehensiveness of the guidelines in tack-
ling data sharing concerns. It would also
require oversight mechanisms to ensure that
data users and producers adhere to such
guidelines.
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Suggested Minimal Guidelines
• Developing access arrangements and
communicating them sufficiently to data
users will reinforce transparency and facil-
itate wider access to databases.
• A deeper involvement of funding organiza-
tions in developing access arrangements
and setting up data access committees
would be especially beneficial for small
studies with limited resources.
• Harmonization of data access arrange-
ments is necessary for successful interna-
tional data sharing and to ensure fairness
of the procedure.
• Data subjects’ concerns at the individual
and group levels should be identified and
respected.
• Oversight mechanisms on the enforcement
of data access agreements and standards
should be elaborated and arrangements
made for detection and sanction of viola-
tions.
• To avoid redundancies, the relationship
between data access committees and other
oversight bodies such as ethics committees
and the scope of their oversight should be
clarified.
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